Format

Send to

Choose Destination
Transfus Med Hemother. 2013 Oct;40(5):319-25. doi: 10.1159/000355006. Epub 2013 Sep 11.

Clinical indications for thrombopoietin and thrombopoietin-receptor agonists.

Author information

1
Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorbiologie, Ambulantes Gesundheitszentrum, Charité Universitätsmedizin Berlin - Campus Virchow Klinikum, Berlin, Germany ; Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Berlin, Germany.

Abstract

Thrombocytopenia is a common hematologic disorder. Stimulation of thrombopoiesis may reduce the risk for thrombocytopenia-induced bleeding, prevent severe thrombocytopenia, and reduce the need for platelet transfusion. The key cytokine is thrombopoietin (TPO). It regulates proliferation and maturation of megakaryocytes as well as platelet production. TPO is synthesized in the liver. Development of TPO from the laboratory into a therapeutic tool has turned out to be an unexpected challenge. Clinical trials on first-generation thrombopoietic growth factors were stopped in 2001. At present, second-generation thrombopoiesis-stimulating agents have only been approved as orphan drugs for third-line therapy of patients with chronic immune thrombocytopenia. Larger groups in need are patients with myelodysplastic syndrome, chemotherapy-induced thrombocytopenia, other forms of hereditary and acquired bone marrow failure, hepatitis C infections, or liver cirrhosis.

KEYWORDS:

Cirrhosis; Eltrombopag; ITP; Myelodysplastic syndrome; Romiplostim

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center